According to an August 8, 2024, Sanofi press release, "Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant." This conclusion was based on new results from "the two-part, double-randomized, German-speaking Myeloma Multicenter Group (GMMG)-HD7 phase 3 study."

This study looked at "the combination of Sarclisa (isatuximab) in combination with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (VRd) during induction therapy in transplant-eligible, newly diagnosed multiple myeloma (NDMM)."

The new treatment helped patients stay healthier for longer by "prolonging progression-free survival." It lowered the chance of disease progression or causing death. This improvement was clear when compared to the usual VRd treatment, no matter what maintenance care the patients received.

To learn more about the GMMG-HD7 study, read the full press release from the button below.